## 3 Results  
The genotype frequencies in our populations for both SNPs (Table 2) were in Hardy Weinberg equilibrium and did not differ significantly from those observed among the European subjects as reported in the database gnomAD [25]. The phase of the two SNPs was not considered due to the number of subjects analyzed and the allelic frequencies observed. The baseline characteristics of the 172 asthmatics enrolled are shown in Table 3. Moderate-to-severe asthmatics (N = 85) were older, had more asthma exacerbations in the last year, and had higher blood eosinophils compared to mild asthmatics. Furthermore, these patients had a frequent exacerbate phenotype, a higher prevalence of blood eosinophils >300 cells/uL; LABA and LAMA medications, Omalizumab and OCS use than mild asthmatics. No significative differences were observed for what concerns the comorbidities. \begin{table}
\begin{tabular}{c c c c c c c c c c} \hline \hline
**refSNP** & **Alias** & **Change at the** & **Sequence** & **Ref** & **Alt** & **Genotype Frequencies** & \multicolumn{2}{c}{**Alleic**} \\  & **DNA Level** & **Term** & **Allele** & **Allele** & & **(N)** & & **Frequencies** \\ \hline  & & & & & GG & GC & CC & G & C \\ rs41423247 & Bcl & c.1184+646C\textgreater{}G & \multirow{2}{*}{Intron Variant} & \multirow{2}{*}{G} & \multirow{2}{*}{C} & 0.10 & 0.44 & 0.46 & 0.54 & 0.46 \\  & & & & & & (18) & (75) & (79) & 0.54 & 0.46 \\ \hline  & & & & & GG & AG & AA & & \\ rs6198 & A3669G & c.*3833A\textgreater{}G & \(\begin{array}{c}3^{\prime}\text{ UTR}\\ \text{Variant}\end{array}\) & \multirow{2}{*}{A} & \multirow{2}{*}{G} & 0.06 & 0.40 & 0.54 & 0.29 & 0.71 \\ \cline{5-5}  & & & & (11) & (68) & (93) & & \\ \hline \hline \end{tabular}
\end{table} 
Table 2: Single nucleotide polymorphisms frequencies in the asthmatic population (N = 172). \begin{table}
\begin{tabular}{c c c c} \hline \hline  & **All Population (N = 172)** & **Mild Asthma (N = 87)** & \multicolumn{2}{c}{**Moderate-Severe**} \\  & **Asthma \({}^{\dagger}\) (N = 85)** \\ \hline Age (years) & 58.4 \(\pm\) 14.0 & 55.7 \(\pm\) 14.4 & 61.1 \(\pm\) 13.1 \({}^{\ast}\) \\ \hline Gender (F) & 109/172 (63.4\%) & 54/86 (62.8\%) & 55/86 (63.9\%) \\ \hline BMI (Kg/m\({}^{2}\)) & 26.7 \(\pm\) 5.4 & 26.2 \(\pm\) 5.8 & 27.3 \(\pm\) 5.0 \\ \hline Current smokers (\(\geq\)10 PY) & 42/172 (24.4\%) & 17/87 (19.5\%) & 25/85 (29.4\%) \\ \hline Former smokers (\(\geq\)10 PY) & 1/172 (0.6\%) & 0/86 (0.0\%) & 1/85 (1.2\%) \\ \hline Atopy & 100/172 (58.1\%) & 53/87 (60.9\%) & 47/85 (55.3\%) \\ \hline Poly-sensitization & 81/100 (81.0\%) & 45/53 (84.9\%) & 36/47 (76.6\%) \\ \hline Asthma exacerbations/year & 1.3 \(\pm\) 1.5 & 0.7 \(\pm\) 0.9 & 1.9 \(\pm\) 1.7 *** \\ \hline FE Phenotype & 54/172 (31.4\%) & 12/87 (13.8\%) & 42/85 (49.4\%) *** \\ \hline Serum IgE (kU/L) & 275.3 \(\pm\) 435.7 & 194.0 \(\pm\) 206.8 & 342.4 \(\pm\) 550.7 \\ \hline Serum IgE >100 kV/L & 78/135 (57.8\%) & 35/61 (57.4\%) & 43/74 (58.1\%) \\ \hline F\({}_{\text{E}}\)NO (ppb) & 38.8 \(\pm\) 27.2 & 36.5 \(\pm\) 27.3 & 41.1 \(\pm\) 27.1 \\ \hline F\({}_{\text{E}}\)NO > 30 ppb & 74/154 (48.0\%) & 33/76 (43.4\%) & 41/78(52.5\%) \\ \hline Blood eosinophils (cells/uL) & 354.2 \(\pm\) 287.5 & 300.5 \(\pm\) 234.7 & 408.6 \(\pm\) 325.0 \({}^{\ast}\) \\ \hline \hline \end{tabular}
\end{table} 
Table 3: Descriptive statistics in the asthmatic population. The Bcl and A3669G SNPs genotype and allele frequencies in our asthmatics are reported in Tables 4 and 5, respectively.